Streetbeat News

Stock Prices

LLY

Eli Lilly & Co. is investing $800 million in its Irish operations to increase production of its obesity drugs, Mounjaro and Zepbound, amid high demand and past shortages. This move is part of a broader strategy to expand production capacity for its weight-loss and diabetes drugs.

Portfolio Pulse from Pooja Rajkumari

September 12, 2024 | 2:05 pm

AAOI

Analysts have provided mixed ratings for Applied Optoelectronics (NASDAQ:AAOI), with a recent positive shift in average price targets. The company's financial performance shows revenue growth but challenges in profitability and asset utilization.

Portfolio Pulse from Benzinga Insights

September 12, 2024 | 2:05 pm

SRE

In the past three months, six analysts have provided ratings on Sempra (NYSE:SRE), with a mix of somewhat bullish and indifferent sentiments. The average 12-month price target has increased to $84.0, indicating a positive outlook. Despite a recent revenue decline, Sempra's financial metrics like net margin and ROE remain strong.

Portfolio Pulse from Benzinga Insights

September 12, 2024 | 2:05 pm

BEN

Analysts have mixed opinions on Franklin Resources (NYSE:BEN), with most ratings being indifferent or somewhat bearish. The average 12-month price target has decreased by 7.98% to $22.6. Despite positive revenue growth, the company faces challenges with low net margin, ROE, and ROA compared to industry averages.

Portfolio Pulse from Benzinga Insights

September 12, 2024 | 2:05 pm

LLY

Recent options trading trends for Eli Lilly (NYSE:LLY) show a bearish sentiment among financial giants, with 40% of traders bearish and 31% bullish. Notable trades include 3 puts valued at $79,790 and 19 calls valued at $3,152,686. Analysts have set price targets ranging from $885 to $1106, with a current stock price of $921.59.

Portfolio Pulse from Benzinga Insights

September 12, 2024 | 2:05 pm

HOLX

Hologic (NASDAQ:HOLX) has outperformed the market over the past 20 years, achieving an average annual return of 14.78%. A $1000 investment in HOLX 20 years ago would now be worth $16,165.24. The article highlights the power of compounded returns over time.

Portfolio Pulse from Benzinga Insights

September 12, 2024 | 2:05 pm

BX

Analysts have provided a range of ratings for Blackstone (NYSE:BX) over the past three months, with a mix of bullish and neutral sentiments. The average 12-month price target has increased by 7.22% to $142.2. Blackstone, the largest alternative-asset manager, faces challenges with a revenue decline and high debt levels, but shows strong ROE. Analysts' ratings reflect their response to market conditions and company performance.

Portfolio Pulse from Benzinga Insights

September 12, 2024 | 2:05 pm

MODV

ModivCare shares experienced a significant price movement, triggering a circuit breaker to the upside. Despite this, the stock is still down 56.9%.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 2:05 pm

EVR

Evercore (NYSE:EVR) has received mixed analyst ratings over the past three months, with a recent increase in the average 12-month price target to $240. Analysts have raised their price targets, reflecting positive sentiment. Evercore's financial performance shows strong revenue growth and effective asset utilization, but challenges in profitability remain.

Portfolio Pulse from Benzinga Insights

September 12, 2024 | 2:05 pm

MRNA

Moderna Inc (NASDAQ:MRNA) has outlined its post-COVID strategy, focusing on mRNA-based vaccines and reducing its R&D budget. The company plans to cut R&D spending by $1.1 billion by 2027, focusing on oncology and rare diseases. Moderna projects 2025 sales below expectations, with a revenue forecast of $2.5 to $3.5 billion, compared to the consensus of $3.74 billion. The stock is down 17.60% following the announcement.

Portfolio Pulse from Vandana Singh

September 12, 2024 | 2:05 pm